Trauma-related nightmares in posttraumatic stress disorder (PTSD) rarely respond to pharmacologic treatment. Neurobiologic data suggest that enhanced brain responsiveness to adrenergic stimulation may contribute to the pathophysiology of trauma-related nightmares in PTSD. Nine older men with chronic PTSD secondary to military or Holocaust trauma were prescribed the lipophilic alpha-1 adrenergic antagonist prazosin for treatment-resistant trauma-related nightmares. Prazosin 2 mg to 4 mg 1 hour before bedtime substantially reduced nightmares and moderately or markedly reduced overall PTSD severity in 8 of 9 subjects. Prazosin was well tolerated. These open-label results are consistent with demonstrated therapeutic efficacy of prazosin for PTSD nightmares and sleep disturbance in a recent placebo-controlled trial in Vietnam veterans. (J Geriatr Psychiatry Neurol 2003; 16:165-171).
Get full access to this article
View all access options for this article.
References
1.
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
2.
2. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry1995; 52:1048-1060.
3.
3. Nichols BL, Czirr R. Post-traumatic stress disorder: hidden syndrome in elders. Clin Gerontol1986; 5:417-433.
4.
4. Spiro A, Schnurr PP, Aldwin CM. Combat-related posttraumatic stress disorder symptoms in older men. Psychol Aging1994; 9:17-26.
5.
5. Clipp EC, Elder GH. The aging veteran of World War II: psychiatric and life course insights. In: Ruskin PE, Talbott JA, eds. Aging and posttraumatic stress disorder. Washington, DC: American Psychiatric Press, 1996:19-51.
6.
6. Lee KA, Vaillant GE, Torrey WC, et al. A 50-year-old prospective study of the psychological sequelae of World War II combat. Am J Psychiatry1995; 152:516-522.
7.
7. Chara PJ Jr, Chara KA. Posttraumatic stress disorder among survivors of a kamikaze attack. Psychological Reports2001; 89:577-582.
8.
8. Dirkzwager AJE, Bramsen I, Van Der Ploeg HM. The longitudinal course of posttraumatic stress disorder symptoms among aging military veterans. J Nerv Ment Dis2001; 189:846-853.
9.
9. Engdahl B, Dikel TN, Eberly R, et al. Posttraumatic stress disorder in a community group of former prisoners of war: a normative response to severe trauma. Am J Psychiatry1997; 154:1576-1581.
10.
10. Lindman Port C, Engdahl B, Frazier P. A longitudinal and retrospective study of PTSD among older prisoners of war. Am J Psychiatry2001; 158:1474-1479.
11.
11. Yehuda R, Kahana B, Schmeidler J, et al. Impact of cumulative lifetime trauma and recent stress on current posttraumatic stress disorder symptoms in Holocaust survivors. Am J Psychiatry1995; 152:1815-1818.
12.
12. Schnurr PP, Spiro A. Combat exposure, posttraumatic stress disorder symptoms, and health behaviors as predictors of self-reported physical health in older veterans. J Nerv Ment Dis1999; 187:353-359.
13.
13. Neylan TC, Marmer CR, Metzler TJ, et al. Sleep disturbance in the Vietnam generation: findings from a nationally representative sample of male Vietnam veterans. Am J Psychiatry1998; 155:929-933.
14.
14. Geracioti TD Jr, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry2001; 158:1227-1230.
15.
15. Southwick SM, Krystal JH, Morgan CA, et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry1993; 50:266-274.
16.
16. Mellman TA, Kumar A, Kulick-Bell R, et al. Nocturnal/daytime urine noradrenergic measures and sleep in combat-related PTSD. Biol Psychiatry1995; 38:174-179.
17.
17. Bremner JD, Licinio J, Darnell A, et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry1997; 154:624-629.
18.
18. Baker DG, West SA, Nicholson WE, et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry1999; 156:585-588.
20. Kalin NH, Shelton SE, Davidson RJ. Cerebrospinal fluid corticotropin-releasing hormone levels are elevated in monkeys with patterns of brain activity associated with fearful temperament. Biol Psychiatry2000; 7:579-585.
21.
21. Vynthilingam M, Anderson GM, Owens MJ, et al. Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. J Clin Endocrinol Metab2000; 85:4138-4145.
22.
22. Pickworth WB, Sharpe LG, Nozaki M, et al. Sleep suppression induced by intravenous and intraventricular infusions of methoxamine in the dog. Exp Neurol1977; 57:999-1011.
23.
23. Birnbaum S, Gobeske KT, Auerbach J, et al. A role for norepinephrine in stress-induced cognitive deficits: alpha 1-adrenore-ceptor mediation in the prefrontal cortex. Biol Psychiatry1999; 46:1266-1274.
25. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry2003; 160:371-373.
26.
26. Raskind MA, Dobie DJ, Kanter ED, et al. The alpha-1 adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder. J Clin Psychiatry2000; 61:129-133.
27.
27. Raskind MA, Thompson C, Petrie EC, et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry2002; 63:565-568.
28.
28. Taylor F, Raskind MA. The alpha-1 adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma post-traumatic stress disorder. J Clin Psychopharm2002; 22:82-85.
29.
29. Raskind MA, Peskind ER, Holmes C, Goldstein DS. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol Psychiatry1999; 46:756-765.
30.
30. Supiano MA, Linares OA, Smith MJ, Halter JB. Age-related differences in norepinephrine kinetics: effect of posture and sodium restricted diet. Am J Physiol1990; 259:E422-E431.
31.
31. Lund Johansen P, Hjermann I, Iversen BM, et al. Selective alpha-1 inhibitors: first- or second-line antihypertensive agents? Cardiology1993; 83:150-159.
32.
32. Hieble JP, Ruffulo RR Jr. The use of alpha-adrenoreceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res1996; 33:145-160.
33.
33. Friedman MJ. Drug treatment for PTSD: answers and questions. Ann NY Acad Sci1997; 821:359-371.
34.
34. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress1995; 8:75-90.
35.
35. Brady K, Pearlstein T, Asni GM, et al. Efficacy and safety of sertraline in posttraumatic stress disorder. JAMA2000; 283:1837-1844.
36.
36. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo controlled study. Am J Psychiatry2001; 158:1982-1988.
37.
37. Folstein MF, Folstein SE, McHugh PH. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12:189-198.
38.
38. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2001; 56:1131-1132.
39.
39. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: NIMH; DHEW Publication, 1976.
40.
40. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry1994; 55:517-522.
41.
41. Zohar J, Amital D, Miodownik C, et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with post-traumatic stress disorder. J Clin Psychopharmacol2002;22:190-195.
42.
42. Peskind ER, Wingerson D, Murray S, et al. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry1995; 52:774-782.
43.
43. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:229.
